ByTrending Posts
Does the U.S. Exit from WHO Redefine Global…
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Does the U.S. Exit from WHO Redefine Global…
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS…
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics, a…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS…
22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics,…
Can Global Partnerships Future-Proof Epidemic Preparedness? SK bioscience,…
23 January 2026 Executive Summary A global vaccine partnership has been established between SK bioscience, MSD (Merck &…
Is Strategic Out-Licensing the Fastest Path to Global…
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…
Is GSK Buying Its Way Past the Patent…
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
Is AI Poised to Replace the Traditional Drug…
23 January 2026 Executive Summary Nvidia CEO Jensen Huang has underscored the transformative potential of artificial intelligence in…
Is Short-Term Cost Control Undermining Long-Term Innovation? Novartis…
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Trending Posts
Latest Stories
BMS’s Chinese-Licensed ADC CC-1234 Delivers 52% ORR, 14-Month PFS in Aggressive HER2-Low Breast Cancer
Published by BioNextAI Media – Bristol Myers Squibb (NYSE: BMY) unveiled compelling Phase 2 data for…
Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies
Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO…
BioMarin’s Roctavian Withdrawal—$240M Q4 Charge, <200 U.S. Patients Served Amid Gene Therapy Market Reality Check
Published by BioNextAI Media – BioMarin Pharmaceutical Inc. voluntarily withdrew its pioneering hemophilia A gene therapy…
Gallery
